Gilead’s divestment from a 50-50 joint venture with local partner, which came to light recently, will leave China’s cell therapies market under the total control of domestic players in the coming years.

Restructuring Edition: BioMarin’s layoffs are associated with strategic shifts announced during its second quarter update. Also, Repare reduced its workforce by 25% as it focused in on clinical-stage programs and Aadi cut 80% of its R&D team to conserve cash after a clinical trial failure. 

Plus deals involving AstraZeneca/Conduit, Recursion/Exscientia, G1/Pharmacosmos, Sanofi/Vir, Passage Bio/GEMMA and Lupin/Evofem. Also including deals in brief.

Unilabs and C2N Diagnostics signed a multi-year agreement that will expand access to C2N’s Alzheimer’s tests in Europe and other countries.